Dudediligence.

iBio, Inc

IBIONASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Sep ’24$200,000Dec ’24$0.00Mar ’25$200,000Jun ’25$100,000Sep ’25$0.00Dec ’25$0.00Mar ’26$0.00Jun ’26
Net income, by quarter
−$4.0MSep ’24−$4.4MDec ’24−$4.9MMar ’25−$5.2MJun ’25−$5.7MSep ’25−$9.0MDec ’25−$7.7MMar ’26−$10.4MJun ’26
Fiscal years, by the month each ended
LineJun 2022Jun 2023Jun 2024Jun 2025Jun 2026
Revenue$1.9M$0.00$225,000$400,000$100,000
Gross profit$2.2Mnone on filenone on filenone on filenone on file
Operating income−$29.7M−$29.3M−$16.6M−$18.6M−$35.1M
Net income−$50.3M−$65.0M−$24.9M−$18.4M−$32.8M
Operating cash flow−$37.5M−$30.4M−$18.6M−$15.3M−$23.2M
Free cash flow−$44.8M−$36.2M−$18.8M−$15.3M−$23.8M
Cash$22.7M$4.3M$14.2M$8.6M$56.4M
Shares outstanding8.7M1.0M8.6M19.3M55.7M